FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Sanofi-Aventis

Sanofi-Aventis gets bullish on booming vax sales

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Sanofi-Aventis has been a big winner in the race to capitalize on the swine flu pandemic with a new vaccine, and today it tempted investors with plans to double its vaccine sales by 2013. Sanofi also echoed earlier remarks that it may turn to acquisitions to help bolster its vaccine business.

In an investor presentation earlier today, Sanofi projected that it will earn $5.76 billion in vaccine income in 2010 and added that H1N1 vaccine sales would contribute $500 million to its earnings for the fourth quarter of this year. And Wayne Pisano, who runs Sanofi Pasteur, forecast that the global vaccine market will hit 23 billion euros by 2013.

Sanofi has been one of the most aggressive of the multi-national pharma companies. CEO Chris Viehbacher (photo), hired in late 2008, has been quick to shed lackluster development programs while striking new deals to help feed future sales growth.

- here's the report from Reuters
- check out the Dow Jones story

Related Articles:
Sanofi chief pleased with H1N1 vax production
Sanofi H1N1 vax a winner at one dose
Viehbacher's $9 billion shopping spree
Sanofi chief bucks conventional pharma wisdom


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Sanofi-Aventis